Harvard Bioscience, Inc.HBIONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -12.78% | -11.17% | -11.46% | -6.28% | -3.34% |
| Gross Profit Growth | -6.21% | -17.52% | -21.54% | -5.83% | -19.30% |
| EBITDA Growth | +118.78% | +0.00% | +0.00% | +0.00% | +1534.16% |
| Operating Income Growth | -96.10% | +0.00% | +0.00% | +0.00% | +451363.64% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -15916.67% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -16100.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -16100.00% |
| Weighted Average Shares Growth | +1.94% | +1.60% | +1.88% | +2.16% | +1.96% |
| Weighted Average Shares Diluted Growth | +1.94% | +1.60% | +1.88% | +2.16% | +1.96% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -59.91% | +112.83% | +0.00% | +0.00% | -105.57% |
| Free Cash Flow Growth | -61.17% | +262.08% | +0.00% | +0.00% | -143.29% |
| Receivables Growth | -7.66% | -11.95% | -4.40% | -5.63% | +7.92% |
| Inventory Growth | -5.95% | -5.47% | -11.44% | -16.88% | -10.50% |
| Asset Growth | -7.81% | -40.07% | -37.87% | -40.57% | -36.77% |
| Book Value per Share Growth | -14.97% | -78.78% | -77.04% | -78.92% | -78.73% |
| Debt Growth | +4.03% | +7.84% | +4.49% | -6.36% | -0.49% |
| R&D Expense Growth | -26.10% | -19.55% | -16.64% | -16.95% | -6.23% |
| SG&A Expenses Growth | -11.37% | -14.42% | -20.58% | -16.76% | -9.67% |